{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:41Z","timestamp":1793401181969,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xops.2026.101087","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:32:58Z","timestamp":1769128378000},"page":"101087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Na\u00efve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report"],"prefix":"10.1016","volume":"6","author":[{"given":"Jan","family":"Spindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Artemiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gabathuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahm","family":"Spitznagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kitsos-Kalyvianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine A.","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor M\u00e1rk","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Kitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ebneter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101087_bib1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101087_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","article-title":"Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration","volume":"9","author":"Bala","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101087_bib4","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.3390\/jcm14144900","article-title":"Efficacy of Aflibercept 8 mg in pretreated age-related macular degeneration","volume":"14","author":"Palm","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101087_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","article-title":"Noninfectious intraocular inflammation after intravitreal aflibercept","volume":"143","author":"Binder","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","article-title":"Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series","volume":"24","author":"Hoffmann","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib7","article-title":"Recurrence of intraocular inflammation following an aflibercept 8-mg injection in eyes with a history of intraocular inflammation from faricimab: a case report","volume":"17","author":"Sato","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.xops.2026.101087_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/ICB.0000000000001757","article-title":"Occlusive retinal vasculitis after aflibercept 8mg injection for wet macular degeneration","author":"Sisk","year":"2025","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.xops.2026.101087_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ICU.0000000000001129","article-title":"Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema","volume":"36","author":"Kalavar","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101087_bib11","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","article-title":"Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial","volume":"39","author":"Garweg","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.xops.2026.101087_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78954-3","article-title":"Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101087_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ophtha.2019.11.018","article-title":"Ranibizumab or Aflibercept for diabetic macular edema: Comparison of 1-year outcomes from the fight retinal blindness! registry","volume":"127","author":"Bhandari","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101087_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2015.12.030","article-title":"Conversion to aflibercept after prior Anti-VEGF therapy for persistent diabetic macular edema","volume":"164","author":"Rahimy","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib15","first-page":"465","article-title":"Efficacy of Aflibercept (8 mg) for diabetic macular edema in vitrectomized eyes refractory to the other Anti-VEGF drug therapies: a report of three cases","volume":"18","author":"Kashiwagi","year":"2025","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.xops.2026.101087_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000504753","article-title":"One-year results of treatment of diabetic macular edema with aflibercept using the treat-and-extend dosing regimen: the VIBIM study","volume":"243","author":"Pak","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.xops.2026.101087_bib17","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/jcm13102778","article-title":"Beyond VEGF: angiopoietin-tie signaling pathway in diabetic retinopathy","volume":"13","author":"Chen-Li","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101087_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/iovs.65.14.46","article-title":"Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema","volume":"65","author":"Huber","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101087_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2026.101087_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/joco.joco_308_21","article-title":"Efficacy and safety of aflibercept therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"34","author":"Santhakumaran","year":"2022","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib22","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101087_bib23","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00417-025-06878-7","article-title":"Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis","volume":"263","author":"Tahmasebi","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101087_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","article-title":"Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report","volume":"25","author":"Hashiya","year":"2025","journal-title":"BMC Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:19:32Z","timestamp":1776241172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666914526000254"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101087","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Na\u00efve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101087"}}